RT info:eu-repo/semantics/masterThesis
T1 G12C: New clinical perspective in Lung Adenocarcinoma
A1 Ramos Navas, Luisa Ayelen
A2 Máster Universitario en Biomedicina Por la Universidad de la Laguna
AB KRAS activating mutations are among the most frequent drivers in humancancer. However, the published series addressing the prevalence of KRASG12C in lung adenocarcinoma are few and controversial. The objective ofthis study is to establish the prevalence of KRAS G12C mutation in lungadenocarcinoma as well as its possible coexistence with mutations in EGFR,ALK and BRAF. Also studying a possible morphological correlation withmutations in KRAS.Three hundred consecutive lung adenocarcinoma stage IIIb and IV casesdiagnosed at the Dept. Pathology, Hospital Universitario de Canarias wereincluded. Tumor genotyping was performed using the KRASpyrosequencing kit (Qiagen).KRAS was mutated in approximately 35% of cases, being KRAS G12C themost frequent mutation. Mutated adenocarcinomas of KRAS could be seenalso carrying mutations in EGFR or BRAF V600E. However, none wasassociated with ALK translocation. Therefore, KRAS mutations do notappear to be mutually exclusive with EGFR or BRAF mutations.No statistically significant association between histology subtypes of lungadenocarcinoma and mutations in KRAS was found, not even the mucinousphenotype, which has been suggested to harbor KRAS mutations in a higherproportion (p=0,318).Due to the recent development of KRAS inhibitors, it seems necessary togenotype KRAS in lung adenocarcinomas using protocols that candistinguish specific alleles since the therapy currently in clinical trials ismutation-specific. Pyrosequencing is a simple, low-cost and fast genopytingmethod for this purpose.
YR 2021
FD 2021
LK http://riull.ull.es/xmlui/handle/915/23123
UL http://riull.ull.es/xmlui/handle/915/23123
LA en
DS Repositorio institucional de la Universidad de La Laguna
RD 12-may-2024